A biopharmaceutical firm focused on discovering.

‘I applaud AVEO’s research initiatives, and the company’s goal of further advancing our knowledge of how biomarkers may eventually improve the treatment and treatment of patients coping with kidney cancer.’.. AVEO Pharmaceuticals to provide tivozanib Phase 2 research results at IKCS Symposium AVEO Pharmaceuticals, Inc. , a biopharmaceutical firm focused on discovering, commercializing and developing a cancer therapeutics, today announced that previously reported outcomes from its Phase 2 research analyzing tivozanib for the treating advanced renal cell carcinoma will be provided at the Ninth International Kidney Cancer tumor Symposium in Chicago, Illinois, October 1-2, 2010.D., Sc.M., chief medical officer at AVEO. ‘We believe that there can be an urgent dependence on a differentiated kidney tumor therapy with strong efficacy and favorable tolerability, and we look forward to continued collaboration with the Kidney Cancer Association, clinicians and sufferers as we make efforts to advance tivozanib toward regulatory approval.’ The Phase 2 clinical trial evaluated tivozanib in 272 patients with advanced RCC.That research showed a similar pattern toward improvement in progression-free of charge survival , with a 3.4-month extension of progression-free survival, although the difference had not been significant according to the prespecified alpha level . No significant difference in overall survival was noticed between the study groups .37 In our study, treatment during progression-free time was associated with a consistently stable standard of living across all domains, sustained functional independence, and a diminished glucocorticoid requirement.